Product Description: AMX-818 is a conditionally active, masked T cell engager (TCE) targeting HER2. AMX-818 demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines. AMX-818 can also induce tumor regression in vivo. AMX-818 is promising for research of HER2-positive solid tumors[1][2].
Formula: N/A
References: [1]Irving B. Abstract ND03: AMX-818: Next generation conditionally active, masked T-cell engager for the treatment of HER2-expressing solid tumors[J]. Cancer Research, 2022, 82(12_Supplement): ND03-ND03./[2]To M, et al. Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)[J]. Molecular Cancer Therapeutics, 2021, 20(12_Supplement): P193-P193.
Molecular Weight: N/A
Research Area: Cancer
Target: EGFR
Deutsch
English
